Search results for "target alpha therapy"

showing 1 items of 1 documents

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

2020

Background Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration. Methods 430 consecutive mCRPC patients were enrolled. Clinical data have been collected at baseline and at the end of the Radium-223 treatment. Furthermore, the overall survival(OS) of our population has been provided. Results 157 patients (36.5%) were still alive at the time of data analysis. A mean numbe…

MaleRadium-223radium-223; mCRPC; prostate cancer; target alpha therapyPediatricsmedicine.medical_specialtyradium-223UrologyPopulationBone NeoplasmsContext (language use)Quality of lifemedicineHumanseducationeducation.field_of_studybusiness.industrymCRPCprostate cancerProstatic Neoplasms Castration-ResistantRegimenSafety profileTreatment OutcomeItalyMulticenter studyNephrologyCohortQuality of LifeSettore SECS-S/01businesstarget alpha therapyRadiummedicine.drugMinerva Urology and Nephrology
researchProduct